Portage Biotech and Biohaven Pharmaceutical announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to BHV-0223 for the treatment of spinocerebellar ataxia (SCA). SCA is a progressive, hereditary, …
Portage Biotech and Biohaven Pharmaceutical announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to BHV-0223 for the treatment of spinocerebellar ataxia (SCA). SCA is a progressive, hereditary, …
By clicking “SUBSCRIBE NOW,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.
